Tailorable Antibacterial Activity and Biofilm Eradication Properties of Biocompatible α-Hydroxy Acid-Based Deep Eutectic Solvents; Pharmaceutics; Vol. 18, iss. 1

Dettagli Bibliografici
Parent link:Pharmaceutics.— .— Basel: MDPI AG
Vol. 18, iss. 1.— 2026.— Article number 16, 25 p.
Altri autori: Dubinenko G. E. Gleb Evgenjevich, Senkina E. I. Elena Ivanovna, Golovina K. A. Kseniya Aleksandrovna, Myshova A. E. Aleksandra Evgenjevna, Igumnova O. A. Olga Alekseevna, Plotnikov E. V. Evgeny Vladimirovich, Badaraev A. D. Arsalan Dorzhievich, Rutkowski S. Sven, Filimonov V. D. Viktor Dmitrievich, Tverdokhlebov S. I. Sergei Ivanovich
Riassunto:Title screen
Background/Objectives: Deep eutectic solvents (DESs) have recently gained attention for their antimicrobial properties, particularly because they target both planktonic bacteria and biofilms. Among these, DESs based on α-hydroxy acids (αHAs) are of interest due to their inherent antibacterial properties and favorable biocompatibility. However, effects of the αHA molecular structure and hydrogen bonding ability within a DES formulation on biological activity has not yet been thoroughly investigated. Methods: This study systematically investigates DESs formed by combining glycolic acid, lactic acid or tartaric acid with either choline chloride or tetraethylammonium chloride. Results: All DESs demonstrate broad-spectrum antibacterial activity against Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa and effectively inhibit biofilm formation while exhibiting low cytotoxicity toward 3T3-L1 fibroblasts. Conclusions: DES formation enhances antibacterial efficacy while attenuating cytotoxicity compared to the individual components, thereby decoupling bactericidal activity from toxicity. Physicochemical characterization confirms the formation of a eutectic phase and reveals that biological activity is primarily governed by acidity rather than by the specific αHA structure or eutectic strength. These results provide new insights into structure-function relationships in DESs and establish a design strategy for biocompatible, non-cytotoxic antimicrobial agents
Текстовый файл
Lingua:inglese
Pubblicazione: 2026
Soggetti:
Accesso online:https://doi.org/10.3390/pharmaceutics18010016
Natura: Elettronico Capitolo di libro
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=687220

MARC

LEADER 00000naa0a2200000 4500
001 687220
005 20260701112738.0
090 |a 687220 
100 |a 20260701d2026 k||y0rusy50 ba 
101 0 |a eng 
102 |a CH 
135 |a drcn ---uucaa 
181 0 |a i   |b  e  
182 0 |a b 
183 0 |a cr  |2 RDAcarrier 
200 1 |a Tailorable Antibacterial Activity and Biofilm Eradication Properties of Biocompatible α-Hydroxy Acid-Based Deep Eutectic Solvents  |f Gleb Dubinenko, Elena Senkina, Ksenia Golovina [et al.] 
203 |a Текст  |b визуальный  |c электронный 
283 |a online_resource  |2 RDAcarrier 
300 |a Title screen 
320 |a References: 81 tit 
330 |a Background/Objectives: Deep eutectic solvents (DESs) have recently gained attention for their antimicrobial properties, particularly because they target both planktonic bacteria and biofilms. Among these, DESs based on α-hydroxy acids (αHAs) are of interest due to their inherent antibacterial properties and favorable biocompatibility. However, effects of the αHA molecular structure and hydrogen bonding ability within a DES formulation on biological activity has not yet been thoroughly investigated. Methods: This study systematically investigates DESs formed by combining glycolic acid, lactic acid or tartaric acid with either choline chloride or tetraethylammonium chloride. Results: All DESs demonstrate broad-spectrum antibacterial activity against Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa and effectively inhibit biofilm formation while exhibiting low cytotoxicity toward 3T3-L1 fibroblasts. Conclusions: DES formation enhances antibacterial efficacy while attenuating cytotoxicity compared to the individual components, thereby decoupling bactericidal activity from toxicity. Physicochemical characterization confirms the formation of a eutectic phase and reveals that biological activity is primarily governed by acidity rather than by the specific αHA structure or eutectic strength. These results provide new insights into structure-function relationships in DESs and establish a design strategy for biocompatible, non-cytotoxic antimicrobial agents 
336 |a Текстовый файл 
461 1 |t Pharmaceutics  |c Basel  |n MDPI AG 
463 1 |t Vol. 18, iss. 1  |v Article number 16, 25 p.  |d 2026 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a deep eutectic solvents 
610 1 |a α-hydroxy acids 
610 1 |a quaternary ammonium compounds 
610 1 |a choline chloride 
610 1 |a tetraethylammonium chloride 
610 1 |a antibacterial 
610 1 |a antibiofilm 
701 1 |a Dubinenko  |b G. E.  |c Specialist in the field of material science  |c Engineer of Tomsk Polytechnic University  |f 1992-  |g Gleb Evgenjevich  |9 21551 
701 1 |a Senkina  |b E. I.  |g Elena Ivanovna 
701 1 |a Golovina  |b K. A.  |g Kseniya Aleksandrovna 
701 1 |a Myshova  |b A. E.  |g Aleksandra Evgenjevna 
701 1 |a Igumnova  |b O. A.  |g Olga Alekseevna 
701 1 |a Plotnikov  |b E. V.  |c chemist  |c Associate Professor of Tomsk Polytechnic University, Candidate of Chemical Sciences  |f 1983-  |g Evgeny Vladimirovich  |9 16417 
701 1 |a Badaraev  |b A. D.  |c Physicist  |c Engineer of Tomsk Polytechnic University  |f 1995-  |g Arsalan Dorzhievich  |9 22441 
701 1 |a Rutkowski  |b S.  |c chemist  |c Research Engineer, Tomsk Polytechnic University, Ph.D  |f 1981-  |g Sven  |9 22409 
701 1 |a Filimonov  |b V. D.  |c Russian chemist  |c Professor of the TPU  |f 1945-  |g Viktor Dmitrievich  |9 12127 
701 1 |a Tverdokhlebov  |b S. I.  |c physicist  |c Associate Professor of Tomsk Polytechnic University, Candidate of physical and mathematical science  |f 1961-  |g Sergei Ivanovich  |9 15101 
801 0 |a RU  |b 63413507  |c 20260701 
850 |a 63413507 
856 4 0 |u https://doi.org/10.3390/pharmaceutics18010016  |z https://doi.org/10.3390/pharmaceutics18010016 
942 |c CF